...director, clinical and regulatory development. Cooper was CMO at Anokion S.A.Swedish dendritic cell therapy company Immunicum AB...
...named Jereon Rovers as CMO. Rovers is managing director and CMO of DCprime B.V., which merged with Immunicum...
...she was previously CMO of Versantis AG. BC Staff Orphazyme A/S Karolinska Development AB Kadmon Holdings Inc. Abivax S.A. InnoCare Pharma Ltd. Immunicum AB Ropes...

...January 2020 was approved as the first-ever treatment for adults with a rare thyroid eye disease.Immunicum...
...– Insulin-like growth factor-1 (IGF-1) receptor Karen Tkach Tuzman Eli Lilly and Co. Eiger BioPharmaceuticals Inc. Halozyme Therapeutics Inc. Schroedinger Inc. Immunicum AB DCprime...

...company as a scientific and business consultant. Lewis was managing director of shareholder services at Uline Inc.Immunicum AB...

...Relations Officer Sun Kim will assume Amitay’s responsibilities until a successor is found. Immuno-oncology company Immunicum AB...
...of strategy at Ovid Therapeutics Inc. (NASDAQ:OVID). Robin Sawka, BioCentury Staff Evox Therapeutics Ltd. BridgeBio Artax Biopharma Inc. Nucleix Ltd. IsoPlexis Corp. Centogene Immunicum AB CohBar...

...Immunicum's cell therapy misses survival endpoint in Phase II RCC trial Immunicum AB (SSE:IMMU) lost SEK1.46 (14%...
...cell carcinoma. The second primary endpoint of median overall survival has not yet been reached. Immunicum...
...2020 and Feb. 26, 2020, respectively. Sandi Wong, Staff Writer ACX-362E (GLS-362E) bempedoic acid/ezetimibe Ilixadencel (intuvax) Acurx Pharmaceuticals LLC Esperion Therapeutics Inc. Immunicum AB Bacterial...

...effective this year. The cancer and infectious disease company is seeking a replacement. Immuno-oncology company Immunicum AB...

...Immuno-oncology company Immunicum AB (SSE:IMMU) said it began trading on NASDAQ Stockholm on Jan. 15. The company...
...on Jan. 15. The company had traded on Stockholm First North. Immunicum AB (SSE:IMMU), Gothenburg, Sweden Chris Lieu Immunicum AB...

...meeting in National Harbor. Immunicum said it added 6 additional first-line patients to the trial. Immunicum AB...
...Group (ECOG) scores, body weight and systemic immunological response Status: Phase I/II data Milestone: NA Alex Himes Intuvax Immunicum AB Society...

...Phase I/II trial showed that Intuvax led to an average survival of about 14 months. Immunicum...
...a significant reduction in the number of natural killer (NK) cells in the blood, which Immunicum...
...surrounding healthy kidney tissue, suggesting tumor specificity. Pfizer Inc. (NYSE:PFE, New York, N.Y.) markets Sutent. Immunicum AB...